ArticleInflammation research : official journal of the European Histamine Research Society ... [et al.]2022
The combination of metabolic syndrome and inflammation increased the risk of colorectal cancer.
Article in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- The association between serum lipid levels and colorectal cancer risk: A dose-response meta-analysis of 23 studies.PloS one · 2025Pooled it
- Fine particulate matter and tobacco product exposure exacerbates metabolic syndrome-related colon cancer via regulating oxidative stress and tumor-associated macrophage interactions.Cancer & metabolism · 2026Article
- Decoding the gut-adipose-ovary axis in polycystic ovary syndrome: from metabolic dysregulation to oncological risk modulation.Frontiers in microbiology · 2026Review
- Metabolic syndrome and colorectal cancer: Mechanisms, epidemiological evidence, and clinical implications.World journal of clinical oncology · 2025Review
- Ideal cardiovascular health (CVH) behaviour is associated with a lower presence of colorectal adenomas and serrated polyps.BMC public health · 2025Article
- The association of life's essential 8 scores trajectory patterns with the risk of all cancer types.Scientific reports · 2025Article
- Metabolic Phenotype and Risk of Obesity-Related Cancers in the Women's Health Initiative.Cancer prevention research (Philadelphia, Pa.) · 2025Article
- Novel metabolic prognostic score for predicting survival in patients with cancer.Scientific reports · 2025Article
- Metabolic syndrome, high-sensitivity C-reactive protein and the risk of heart failure: the Kailuan cohort study.Frontiers in endocrinology · 2025Article
- Early-onset and later-onset cancer: trends, risk factors, and prevention in Northern China.Science China. Life sciences · 2024Article
- Remnant cholesterol is an effective biomarker for predicting survival in patients with breast cancer.Nutrition journal · 2024Article
- The advent of RNA-based therapeutics for metabolic syndrome and associated conditions: a comprehensive review of the literature.Molecular biology reports · 2024Review
- Article
- Obesity and early-onset colorectal cancer risk: emerging clinical evidence and biological mechanisms.Frontiers in oncology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 1 country.
Funding
Abstract
backgroundInflammation and metabolic syndrome (MetS) may act synergistically and possibly accelerate the initiation and progression of colorectal cancer (CRC). We prospectively examined the joint effect of MetS and inflammation on the risk of CRC.
methodsWe studied 92,770 individuals from the Kailuan study. MetS was defined based on the presence of three or more of the following components. (1) high glucose: FPG > 5.6 mmol/L; (2) high blood pressure: SBP ≥ 130 mmHg or DBP ≥ 85 mmHg; (3) high triglycerides: triglycerides > 1.69 mmol/L; (4) low HDL-C: HDL-C < 1.04 mmol/L in men or 1.29 mmol/L in women; and (5) visceral adiposity: waist circumference ≥ 85 cm in men or 80 cm in women. Inflammation was defined as hs-CRP ≥ 3 mg/L. We divided participants into four groups for the primary exposure according to the presence/absence of inflammation and presence/absence of MetS. Cox proportional hazards regression models were used to evaluate the association of MetS and/or inflammation with the risk of CRC.
resultsCompared with metabolically healthy noninflammatory individuals, inflammatory participants without MetS and inflammatory participants with MetS were associated with a 1.3-fold and 4.18-fold increased risk of CRC with corresponding HRs (95% CI) of 1.34 (1.09, 1.64) and 4.18 (3.11, 5.62), respectively. The combination of MetS and inflammation was associated with the highest risk of CRC in all subgroups, especially among participants who were female, in younger age, and obese. Sensitivity analyses further validated our primary findings.
conclusionsWe found the combination of MetS and inflammation could significantly increase the risk of CRC. Including CRP in the diagnosis of MetS may help to identify additional high-risk participants who should be targeted for early diagnosis and prevention of CRC. Trial registration Kailuan study, ChiCTR-TNRC-11001489. Registered 24 August, 2011-Retrospectively registered, http:// www.chictr.org.cn/showprojen.aspx?proj=8050.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.